SVRA Stock — Savara Inc.: Cash, EV, Pipeline

What they do

Our sole program, molgramostim inhalation solution ("MOLBREEVI " or "molgramostim" ) , is an investigational inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor ("GM-CSF") in Phase 3 development for autoimmune pulmonary alveolar proteinosis (“autoimmune PAP”).

Source: 10-K FY2025 via SEC EDGAR

Share price

$4.83

Market cap

$992.4M

Cash

$173.0M

Enterprise value

$849.5M

Balance sheet

Cash	$173.0M
Debt	$30.1M
Net cash	$142.9M
Enterprise value	$849.5M
Basic shares	205.5M shares
Fully diluted shares	217.7M shares
Fully diluted market cap	$1,051.4M
Cash per share	$0.84
Quarterly burn	$29.7M
Cash runway	5.8 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

205.5M

Pre-funded warrants

0.0M

Options

12.2M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

217.7M

Cap table as of 2026-06-30.

Price history

Loading SVRA daily closes…

Loading price history…

Next catalyst

molgramostim (MOLBREEVI, UK MAA) · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	molgramostim (MOLBREEVI, UK MAA) aPAP, UK MHRA MAA under review	Not disclosed	aPAP, UK MHRA under review	Q4 2026
GUIDEDNov 22, 2026 in 15d	molgramostim (MOLBREEVI, US BLA) autoimmune pulmonary alveolar proteinosis (aPAP), FDA BLA under review	Not disclosed	autoimmune pulmonary alveolar proteinosis (aPAP), FDA under review	November 22, 2026
GUIDEDEst. Feb 14, 2027 in 8 wks quarter midpoint	molgramostim (MOLBREEVI, EU MAA) aPAP, EMA MAA under review	Not disclosed	aPAP, EMA under review	Q1 2027
Jul 13 - Aug 24 in 8 mo	Molgramostim	Phase 3	Autoimmune Pulmonary Alveolar Proteinosis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Molgramostim inhalation solution

Phase 3 · Active Modality: inhaled biologic

Aliases MOLBREEVI

Target GM-CSF (granulocyte-macrophage colony-stimulating factor)

Partnerships RTW Investments: $75M royalty purchase payable on FDA approval by Mar 31, 2027 (royalties 1.0-9.5% of US net sales, capped at $187.5M).

Indications

Autoimmune pulmonary alveolar proteinosis (autoimmune PAP) (Phase 3)

Status note Company's sole program; inhaled GM-CSF in Phase 3 development for autoimmune PAP. No product revenue; not yet commercial.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Molgramostim
Lead indication	Autoimmune Pulmonary Alveolar Proteinosis
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06431776	Phase 3	Recruiting	Sponsor	SVRA	—	Autoimmune Pulmonary Alveolar Proteinosis	Q1 2027 Est. Feb 14, 2027 · quarter midpoint Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT04544293	Phase 3	Active, not recruiting	Sponsor	SVRA	—	Autoimmune Pulmonary Alveolar Proteinosis	Q1 2027 Est. Jan 1, 2027 · PCD + 6 wks (Jan 1-Jan 1) Q4 2026

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Savara Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Deerfield Management	13,569,000	no change	0.87%	2026-08-14
Frazier Life Sciences	9,720,852	no change	1.30%	2026-08-14
RTW Investments	5,952,380	no change	0.31%	2026-08-14
OrbiMed Advisors	3,959,900	+3,324,900	0.46%	2026-08-14
ADAR1 Capital Management	1,403,409	-61,126	0.41%	2026-08-14
Sphera Biotech	756,164	+17,000	0.67%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

SVRA — Savara Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

SVRA — Savara Inc.